The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AI startup OpenEvidence is raising a fresh round of capital from Sequoia to scale its chatbot for doctors. The new $75 ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...